Recardio at ChinaBIO 2026
- Apr 28
- 1 min read
San Francisco, April 28, 2026 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced that it is participating in the ChinaBIO in Shanghai.
The ChinaBio Partnering Forum represents a significant gathering for global leaders, offering a platform for networking, collaboration, and strategic partnerships, with a focus on healthcare solutions and life sciences.
The conference is taking place on April 28-29, 2026 in Shanghai, with a digital partnering component from May 6-7, 2026.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: www.recardio.eu or contact pr@recardio.eu